This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Earnings ESP: Archive
4 Likely Retail Winners Investors Shouldn't Miss This Earnings Season
by Sumit Singh
DG, BURL, URBN and TJX may beat Q3 estimates as value-focused pricing, e-commerce gains and inventory discipline lift retail sales and margins.
retail
2 Business Services Firms Poised to Beat Estimates This Earnings Season
by Shuvra Shankar Dey
QXO and BTDR are set to shine this earnings season, each showing strong growth estimates and solid momentum across the business services sector.
business-services earnings
3 Leisure Stocks Set to Pull Off a Beat This Earnings Season
by Mrithunjoy Kaushik
MasterCraft, Melco Resorts and Planet Fitness are poised for earnings beats as strong demand, innovation and expansion drive sector momentum.
consumer-discretionary earnings
Q3 Energy Earnings: 4 Stocks That Could Surpass Forecasts
by Nilanjan Choudhury
Energy stocks like CNQ, DK, CLMT and NOG have the potential to deliver better-than-expected Q3 earnings.
energy oil-energy
4 Insurance Stocks Set to Pull Off a Beat This Earnings Season
by Sushmita Sarker
Solid retention, renewals, prudent pricing, exposure growth, and improved digitalization are expected to help PRI, CNA, AIZ, and UNM outperform third-quarter estimates.
insurance
4 Internet Stocks Poised to Top Estimates This Earnings Season
by Vasundhara Sawalka
Here, we pick four Internet stocks - LYFT, U, ANET and BILL - that are likely to pull off a beat this earnings season.
artificial-intelligence internet tech-stocks
2 Gold Mining Stocks Poised to Outshine Q3 Earnings Estimates
by Anindya Barman
Gold mining companies' Q3 results are expected to reflect the benefits of higher prices and efforts to reduce costs. B and TFPM look set to beat earnings estimates this season.
basic-materials gold
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
ZYME, NKTR, ANIP, and PCRX are poised for potential Q3 earnings surprises as the biotech sector shows strong momentum.
biotechnology biotechs earnings medical pharmaceuticals
3 MedTech Stocks Positioned to Surpass Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Despite tariff and inflation pressures, innovation-fueled momentum in diabetes care, surgical tech, and cardiovascular devices could drive upside surprises for SOLV, COR and INSP this earnings season.
medical medical-devices
Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3
by Kaibalya Pravo Dey
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
biotechnology earnings insurance medical medical-devices pharmaceuticals